Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

DOPAMINERGIC INHIBITION OF DNA-SYNTHESIS IN PITUITARY-TUMOR CELLS IS ASSOCIATED WITH PHOSPHOTYROSINE PHOSPHATASE-ACTIVITY

DOPAMINERGIC INHIBITION OF DNA-SYNTHESIS IN PITUITARY-TUMOR CELLS IS ASSOCIATED WITH PHOSPHOTYROSINE PHOSPHATASE-ACTIVITY JOURNAL OF BIOLOGICAL CHEMISTRY FLORIO, T., PAN, M. G., NEWMAN, B., HERSHBERGER, R. E., CIVELLI, O., STORK, P. J. 1992; 267 (34): 24169-24172

Abstract

Dopaminergic D2 receptor agonists, such as bromocriptine, are potent anti-proliferative agents in the treatment of human pituitary adenomas. We have reproduced the anti-proliferative effect of dopamine in an established pituitary cell line stably transfected with the rat D2 dopamine receptor cDNA. We found that dopaminergic inhibition of DNA synthesis parallels the stimulation of a phosphotyrosine phosphatase activity. Both actions are blocked by pertussis toxin and by the phosphotyrosine phosphatase inhibitor, vanadate. We suggest that the anti-proliferative action of dopamine is mediated, at least in part, by the dopaminergic stimulation of a phosphotyrosine phosphatase.

View details for Web of Science ID A1992KA26300006

View details for PubMedID 1360008